FIPI is primarily used in research settings as a potent and selective inhibitor of fatty acid amide hydrolase (FAAH), an enzyme responsible for breaking down endocannabinoids like anandamide. By inhibiting FAAH, FIPI increases the levels of endogenous cannabinoids, which helps scientists study the endocannabinoid system’s role in pain, inflammation, mood, and neurodegeneration. It has shown potential in preclinical models for treating anxiety, chronic pain, and inflammatory conditions without the psychoactive effects associated with cannabinoid receptor agonists. Due to its research-focused profile, FIPI is mainly utilized in pharmacological studies to explore new therapeutic pathways and validate drug targets related to the endocannabinoid system.